Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Mechanical stress-induced tissue remodelling

How asthma permanently alters the airways

Asthma attacks induce mechanical forces that permanently alter airway tissue – independently of inflammation. New research used advanced lung-on-a-chip technology to show how this damage occurs.

News • CRISPR-Cas9-based approach

New laboratory tool to find better treatments for resistant melanomas

Researchers have developed a new lab model to study BAP1-deficient melanomas, a rare type of melanoma that evade the immune system once they metastasize and are resistant to current immunotherapies.

News • Treatment-resistant tumours

Researchers tear off "invisibility cloak" of colon cancer

A study from the University of Calgary shows that removing a single gene makes colon cancer cells a target for immunotherapy — a fundamental breakthrough.

Related articles